Business Context and Reporting Period
This Form 8-K was filed by Oculus Innovative Sciences, Inc. on June 7, 2012. The report discloses the issuance of a press release and slide presentation regarding financial results for the fiscal quarter and fiscal year ended March 31, 2012. Note: The request metadata references "Sonoma Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as Oculus Innovative Sciences, Inc.
Key Financial Metrics
The filing text serves as a disclosure notice and does not contain specific numerical data. It references a press release (Exhibit 99.1) and a slide presentation (Exhibit 99.2) for detailed figures. Consequently, the following metrics are not provided in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
The filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes or comparative financial data are detailed within the body of this Form 8-K. The document solely announces the availability of the results for the period ended March 31, 2012, in the attached exhibits.
Guidance, Outlook, and Risks
The filing incorporates forward-looking statements from the attached slide presentation, subject to significant risks and uncertainties. Key risks identified include:
- Changes in regulatory clinical and guideline developments.
- Insufficient scientific data to meet regulatory standards or failure to receive required approvals.
- Inability to replicate clinical results in actual patient settings.
- Challenges to patent protection, including invalidation or circumvention by competitors.
- Market size expectations not being met or failure to penetrate targeted markets.
- Insufficient revenues to fund further development and clinical studies.
- Uncertainty regarding future capital needs and the ability to obtain additional funding.
- Varying product formulations and diverse regulatory/marketing requirements across different countries.
The company disclaims any obligation to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the specific revenue, net income, and cash position figures in the attached Press Release (Exhibit 99.1).
- Review the slide presentation (Exhibit 99.2) for detailed guidance and commercial progress updates.
- Confirm the status of regulatory approvals and clinical trial data referenced in the exhibits.
- Assess the company's current cash runway against the stated capital needs for future development.
- Check for any discrepancies between the metadata company name (Sonoma Pharmaceuticals) and the filing registrant (Oculus Innovative Sciences).